Abbott Laboratories (NYSE:ABT) Receives “Outperform” Rating from Royal Bank Of Canada

Abbott Laboratories (NYSE:ABT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Friday,Benzinga reports. They presently have a $130.00 target price on the healthcare product maker’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 31.57% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Citigroup lowered their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. BTIG Research boosted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday. Robert W. Baird started coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. Finally, Wells Fargo & Company decreased their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.74.

Abbott Laboratories Stock Up 10.7%

ABT opened at $98.81 on Friday. The business has a 50 day moving average of $89.56 and a 200-day moving average of $102.18. The stock has a market capitalization of $172.11 billion, a price-to-earnings ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently bought and sold shares of the business. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, edging past estimates, while revenue rose 13% year over year to $12.51 billion, signaling broad underlying demand. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company lifted its 2026 adjusted EPS guidance to $5.45-$5.60 and kept its comparable sales outlook intact, which investors read as a sign of confidence in second-half momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Growth in medical devices and diagnostics, especially stronger demand for heart devices, helped offset softer areas and supported the upbeat guidance update. Abbott Stock’s Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
• Positive Sentiment: BTIG Research raised its price target to $134 from $131 and reiterated a Buy rating, implying meaningful upside from current levels and adding to the bullish post-earnings sentiment. Benzinga analyst update
• Neutral Sentiment: Several market commentaries highlighted that ABT had been viewed as undervalued or recovering from a prior decline, but these were mostly opinion pieces rather than new fundamentals. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.